RGEN·Repligen Corporation
RGEN|Analyst Targets
RGEN|Insider Trading
RGEN|Fundamentals
RGEN|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $0.46 | - | - |
| Q3'25 | $0.41 | $0.46 | +10.9% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $211M | - | - |
| Q3'25 | - | $189M | - |
RGEN|Monthly Returns
Market Data
RGEN Stock Snapshot
- Market cap
- 10.97B
- P/E ratio
- 264.1
- Day range
- $169.73 – $177.96
- News sentiment
- 43/100 · Neutral
- Analyst target
- $196.70 (+12.1%)
- Consensus
- Buy · 30 analysts
Neither side has the upper hand on RGEN right now, and its momentum ranks near the middle of DailyIQ's universe. Earnings and guidance carry more weight than macro data at this capitalisation.
Reverse DCF
What growth is priced into RGEN?
At today's price, Repligen Corporation needs to grow free cash flow about 60.7% a year for the next 10 years to justify its valuation at a 10.63% cost of capital. Over its actual history it has compounded free cash flow at 26.0% a year, so the market is asking for 34.6 percentage points above its own delivered rate. On that basis RGEN looks priced above what its own growth record supports.
- Implied FCF growth
- 60.7%
- Historical FCF CAGR
- 26.0%
- Growth gap
- +34.6 pts
- Verdict
- RICH
- Discount rate (WACC)
- 10.63%
- Beta
- 1.15
Behaviour On Record
What RGEN's own history says about today's numbers
- Realized volatility (21d)
- 57.2% 80th pct
- Below its peak
- -46.8%
- vs 200-day average
- +21.9%
- Up days (1y)
- 54%
Repligen Corporation is currently running 57.2% annualised volatility over the last 21 sessions. Measured against RGEN's own 13 years of daily returns rather than a market-wide average, that is the 80th percentile — elevated for this stock, against a typical reading of 42.9%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
RGEN is trading -46.8% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -29.7%, and the deepest was -45.5% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.
Price sits +21.9% from its 200-day moving average. Against every other day in its history, that gap ranks at the 76th percentile — a somewhat wider gap than its own norm. Over the past year RGEN closed higher on 54% of sessions, and it is currently 1 session into a rising streak.
On October specifically: over 13 years of records, RGEN finished the month higher 7 of 13 times, with a median return of +2.2% and an average of +2.9%. Its strongest month historically has been July at +8.4% on average, its weakest September at -3.3%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: RGEN has opened more than 2% away from the prior close in 272 of 3,267 sessions (8.3% of the time), with the largest gaps running +28.0% and -10.6%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
All figures computed from 3,268 daily closes between 2013-10-15 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against RGEN's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of RGEN's sector?
Repligen Corporation sits in the Health Care sector, currently ranked 4th of 12 GICS sectors by relative-strength rotation score (improving). Within its narrower Biotechnology industry group, RGEN ranks 11th of 15 tracked industries, lagging.
- Sector rank
- #4 of 12
- Sector state
- Improving
- Sector rotation score
- 82
- Industry rank
- #11 of 15
Analyst Rating Changes
Are analysts turning bullish or bearish on RGEN?
Barclays most recently reiterated its rating on Repligen Corporation to Overweight on Oct 7, 2026 with a price target of $225 (from $175). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- Barclays — Overweight
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
ETF holders
ETFs holding RGEN
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Vanguard Group Inc | ▼ Sell | 4,993,945 | 7.98% | $818.31M | 2026-01-29 |
| BlackRock, Inc. | ▼ Sell | 5,384,938 | 8.61% | $734.72M | 2026-08-07 |
| FMR LLC (Fidelity) | ▲ Buy | 3,326,690 | 5.32% | $453.89M | 2026-08-13 |
| Maverick Capital Ltd | ▲ Buy | 1,984,554 | 3.17% | $270.77M | 2026-08-14 |
| Invesco Ltd. | ▲ Buy | 1,387,242 | 2.22% | $189.28M | 2026-08-14 |
| Geode Capital Management, LLC | ▼ Sell | 1,062,476 | 1.70% | $145.00M | 2026-08-12 |
| Goldman Sachs Group Inc | ▲ Buy | 965,411 | 1.54% | $131.72M | 2026-08-14 |
| William Blair Investment Management, LLC | ▲ Buy | 788,571 | 1.26% | $107.59M | 2026-08-12 |
| AllianceBernstein L.P. | ▼ Sell | 795,282 | 1.27% | $93.70M | 2026-08-14 |
| Norges Bank | ▲ Buy | 575,226 | 0.92% | $78.48M | 2026-08-12 |
| Morgan Stanley | ▼ Sell | 543,242 | 0.87% | $74.12M | 2026-08-13 |
| Northern Trust Corp | ▼ Sell | 444,146 | 0.71% | $60.60M | 2026-08-13 |
| JPMorgan Chase & Co | ▲ Buy | 427,770 | 0.68% | $58.95M | 2026-08-12 |
| Bank of America Corp | ▲ Buy | 426,291 | 0.68% | $58.16M | 2026-08-14 |
| Citadel Advisors LLC | ▼ Sell | 376,309 | 0.60% | $51.34M | 2026-09-02 |
| Balyasny Asset Management L.P. | ▲ Buy | 355,507 | 0.57% | $48.51M | 2026-08-14 |
| Marshall Wace, LLP | ▼ Sell | 282,107 | 0.45% | $38.49M | 2026-08-13 |
| Point72 Asset Management, L.P. | ▼ Sell | 166,157 | 0.27% | $22.67M | 2026-08-14 |
| Loomis Sayles & Co L P | ▼ Sell | 148,676 | 0.24% | $20.29M | 2026-08-14 |
| Gotham Asset Management, LLC | ▲ Buy | 142,613 | 0.23% | $19.46M | 2026-08-14 |
| D. E. Shaw & Co., Inc. | ▼ Sell | 83,328 | 0.13% | $11.37M | 2026-08-14 |
| Verition Fund Management LLC | ▲ Buy | 37,996 | 0.06% | $5.18M | 2026-08-14 |
| Moore Capital Management, LP | ▼ Sell | 37,549 | 0.06% | $5.12M | 2026-08-14 |
| Wells Fargo & Company | ▼ Sell | 33,715 | 0.05% | $4.60M | 2026-08-14 |
| Susquehanna International Group, LLP | ▼ Sell | 21,721 | 0.03% | $2.96M | 2026-08-14 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Lisa McClain | House | MI09 | ▲ Buy | $1K - $15K | 2025-10-30 | 2025-11-21 |
| Lisa McClain | House | MI09 | ▼ Sell | $1K - $15K | 2025-06-17 | 2025-08-13 |
| Lisa McClain | House | MI09 | ▲ Buy | $1K - $15K | 2025-06-11 | 2025-08-13 |
| Jefferson Shreve | House | IN06 | ▼ Sell | $15K - $50K | 2025-04-07 | 2025-05-08 |